Safety data sheet
Standardized safety protocols and material specifications for professional use.
Certificate of Analysis
Purity verified via High-Performance Liquid Chromatography (HPLC) for #myo-ll-37-5mg
LL-37 (5mg)
High >98.5% Purity
Authorized Resellers
Available through our trusted partners
123peptide.com
Netherlands · Europe
local_shipping2-3 Business Days
Depeptidenwinkel.com
Netherlands · Europe
local_shipping2-3 Business Days
Scientific Background
LL-37 is the only known human cathelicidin antimicrobial peptide, derived from the C-terminal region of the human cathelicidin precursor hCAP18. It is a 37-amino acid cationic host defense peptide with a broad spectrum of biological activities spanning innate immunity, wound healing, angiogenesis, and anti-inflammatory signaling.
Originally characterized for its direct antimicrobial properties against gram-positive and gram-negative bacteria, fungi, and enveloped viruses, LL-37 has attracted intense research interest for its broader immunomodulatory effects. It modulates toll-like receptor (TLR) signaling, promotes keratinocyte migration and proliferation, stimulates angiogenesis, and influences neutrophil, monocyte, and dendritic cell function.
Preclinical and early clinical studies have investigated LL-37 in wound healing, inflammatory skin conditions, respiratory infections, and cancer biology. Its dual role as both an antimicrobial agent and an immune modulator makes it a uniquely versatile research compound. As an investigational peptide, LL-37 is not approved for therapeutic use and is provided strictly for research purposes.
Intended Research Use
- Innate immune defense and antimicrobial activity studies (bacteria, fungi, enveloped viruses)
- Wound healing acceleration and keratinocyte migration research
- Angiogenesis and blood vessel formation studies
- Toll-like receptor (TLR) signaling modulation and inflammatory pathway research
- Neutrophil, macrophage, and dendritic cell function investigation
- Anti-biofilm activity and infection prevention research
- Cancer cell apoptosis and tumor microenvironment modulation studies
menu_bookScientific Publications
J Immunol (2003)
The cathelicidin antimicrobial peptide LL-37 modulates epithelial and monocyte/macrophage responses to Toll-like receptor ligands
open_in_newhttps://pubmed.ncbi.nlm.nih.gov/12538677/
Antimicrob Agents Chemother (2006)
LL-37, the only human member of the cathelicidin family of antimicrobial peptides
open_in_newhttps://pubmed.ncbi.nlm.nih.gov/16641312/
J Clin Invest (2009)
Cathelicidin antimicrobial peptide expression in sweat, an innate defense system for the skin
open_in_newhttps://pubmed.ncbi.nlm.nih.gov/19289829/
Wound Repair Regen (2009)
The human cathelicidin LL-37 promotes wound healing by keratinocyte migration
open_in_newhttps://pubmed.ncbi.nlm.nih.gov/19480962/
Nat Chem Biol (2007)
Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica
open_in_newhttps://pubmed.ncbi.nlm.nih.gov/17603538/
J Invest Dermatol (2013)
LL-37 in the inflammatory skin disease rosacea
open_in_newhttps://pubmed.ncbi.nlm.nih.gov/23334344/
Research Note: LL-37 is a uniquely multifunctional host defense peptide. Beyond direct microbial killing via membrane disruption, it acts as a chemoattractant for immune cells, promotes wound re-epithelialization, stimulates angiogenesis via VEGF-R2 activation, and modulates inflammatory signaling through TLR2/4 pathways. This makes it a key model peptide in innate immunity, wound biology, and anti-infective research.
FOR RESEARCH USE ONLY. This product is intended for laboratory research purposes only and is not for human consumption, medical, or diagnostic use.
Possible stacks with other peptides
Synergistic combinations for enhanced research outcomes
LL-37 is researched alongside immunomodulatory, tissue repair, and antimicrobial compounds in preclinical models. Combinations typically target synergistic support for innate immunity, wound healing, or infection biology.
Thymosin Alpha-1 (10mg vial)
arrow_forwardmyo-thymosin-alpha-1-10mg
Complementary immune modulation — LL-37 targets innate immunity while Thymosin Alpha-1 enhances adaptive T-cell responses.
BPC-157 (5mg vial)
arrow_forwardmyo-bpc-157-5mg
Synergistic tissue repair and healing research — BPC-157's angiogenic and cytoprotective properties complement LL-37 wound healing activity.
GHK-Cu (50mg vial)
arrow_forwardmyo-ghk-cu-50mg
Enhanced skin and tissue healing research — GHK-Cu collagen synthesis support combined with LL-37 wound re-epithelialization.
TB-500 (5mg vial)
arrow_forwardmyo-tb-500-5mg
Actin-modulation and tissue repair complement to LL-37 keratinocyte migration and wound healing promotion.
KPV 10mg (10mg vial)
arrow_forwardmyo-kpv-10mg
Anti-inflammatory tripeptide derived from alpha-MSH — complements LL-37's antimicrobial action with targeted cytokine modulation for synergistic wound healing research.
Cycling Note: LL-37 research cycles typically span 4–8 weeks. Rest periods between cycles are recommended to assess baseline immune function and tissue response.